THE CASE OF KAPOSI’S SARCOMA AMONG ELDERLY WOMEN
https://doi.org/10.22625/2072-6732-2016-8-4-88-92
Abstract
The article presents an analysis of a clinical case of a patient of 76 years, describes the key links in the pathogenesis of Kaposi’s sarcoma virus, and the modern concept of participation in the pathogenesis of the disease. A feature of this clinical observation was the development of the disease on the background of the functional immunosuppression, which developed because of old age. Besides the standard protocol of conducting a similar profile of patients therapy led to the development of side effects. In turn, the optimization of the therapeutic protocol has allowed to avoid side effects from the treatment, continue therapy led to complete convalescence.
About the Authors
D. V. ZaslavskyRussian Federation
Saint-Petersburg
S. V. Skrek
Russian Federation
Saint-Petersburg
A. V. Sobolev
Russian Federation
Saint-Petersburg
A. A. Sidikov
Russian Federation
Saint-Petersburg
A. A. Yunovidova
Russian Federation
Saint-Petersburg
P. Wolkenstein
France
Department of Dermatology, Assistance Publique-Hôpitaux de Paris, Créteil
А. V. Truntova
Russian Federation
Saint-Petersburg
L. R. Сhernova
Russian Federation
Saint-Petersburg
References
1. Stiller C.A., Trama A., Brewster D.H, et al. Descriptive epidemiology of Kaposi sarcoma in Europe. Report from the RARECARE project. Cancer Epidemiol 2014; 38:670.
2. Dal Maso L., Polesel J., Ascoli V., et al. Classic Kaposi’s sarcoma in Italy, 1985-1998. Br J Cancer 2005; 92:188.
3. Kaldor J.M., Coates M., Vettom L., Taylor R. Epidemiological characteristics of Kaposi’s sarcoma prior to the AIDS epidemic. Br J Cancer 1994; 70:674.
4. Hiatt K.M., Nelson A.M., Lichy J.H., Fanburg-Smith J.C. Classic Kaposi Sarcoma in the United States over the last two decades: a clinicopathologic and molecular study of 438 nonHIV-related Kaposi Sarcoma patients with comparison to HIVrelated Kaposi Sarcoma. Mod Pathol 2008; 21:572.
5. Cathomas G. Kaposi’s sarcoma-associated herpesvirus (KSHV)/human herpesvirus 8 (HHVas a tumour virus).G Herpes 2003; 10(3):72-7.
6. Eleonora Ruocco, MD, PhDa, Vincenzo Ruocco, MDa, , , Maria Lina Tornesello, PhDb, Alessio Gambardella, MDa, Ronni Wolf, MDc, Franco M. Buonaguro, MDb. Kaposi’s sarcoma: Etiology and pathogenesis, inducing factors, causal associations, and treatments: Facts and controversies. Clinics in Dermatology 2013; 31(4):413-422.
7. Chagaluka G., Stanley C., Banda K., Depani S., Nijram’madzi J., Katangwe T., et al. Kaposi’s sarcoma in children: an open randomised trial of vincristine, oral etoposide and a combination of vincristine and bleomycin. Eur J Cancer 2014; 50(8):1472-81.
8. S. Stewart, H. Jablonowski, F. D. Goebel, K. Arasteh, M. Spittle, A. Rios, D. Aboulafia, J. Galleshaw, B. J. Dezube. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi’s sarcoma. International Pegylated Liposomal Doxorubicin Study Group. JCO 1998; 16 (2):683-91.
9. Solan A.J., Greenwald E.S., Silvay O. Long-term complete remissions of Kaposi’s sarcoma with vinblastine therapy. Cancer. 1981; 47(4):637-9.
10. Escalon M.P. and Hagemeister F.B. AIDS-Related Malignancies. Kantarjian H.M., Wolff Ra., and Koller C.A. MD Anderson Manual of Medical Oncology. McGraw-Hill; 2006; 903-910.
11. DeVita V. Jr., Vincent T., et al. Cancer: Principles and Practice of Clinical Oncology.-fifth edition. – Philadelphia: Lippincott, Williams & Wilkins, 2008. Vol 8: 2404-2407 p.
Review
For citations:
Zaslavsky D.V., Skrek S.V., Sobolev A.V., Sidikov A.A., Yunovidova A.A., Wolkenstein P., Truntova А.V., Сhernova L.R. THE CASE OF KAPOSI’S SARCOMA AMONG ELDERLY WOMEN. Journal Infectology. 2016;8(4):88-92. (In Russ.) https://doi.org/10.22625/2072-6732-2016-8-4-88-92